Bone resorption inhibitors

Bone formation is often reduced by bisphosphonates, which is probably an indirect effect of inhibition of bone resorption. In normal bone remodeling, bone resorption and formation are coupled. Changes in resorption drive formation, so when bone resorption decreases, bone formation also decreases. (See Normal skeletal development and regulation

5 ALFA REDUCTASE INHIBITORS. , IMMUNOMODULATORY AGENTS. , BONE RESORPTION INHIBITORS. , COMPLEMENT INHIBITORS. , DISEASE-MODIFYING

Bisphosphonates are inhibitors of bone resorption. They increase bone mineral density by altering osteoclast activation and function. Alendronate and

All bisphosphonates inhibit bone resorption by attaching to hydroxyapatite binding sites on the bone, particularly in areas with active resorption. As osteoclasts resorb bone, the bisphosphonate embedded in the bone is released and impairs the osteoclast s ability to continue bone resorption.

Another class of bone resorption inhibitors includes bisphosphonates, such as alendronate and zoledronic acid. These drugs bind to bone minerals

Bone resorption inhibitors are drugs that inhibit mineralization or resorption of the bone by blocking the action of osteoclasts. They are used to treat postmenopausal and glucocorticoid induced osteoporosis, Paget's disease of the bone and malignant hypercalcemia.

Bisphosphonates are inhibitors of bone resorption. They increase bone mineral density by altering osteoclast activation and function. Alendronate and

by S Zhou 2024 Cited by 48Currently, the main therapeutic drugs for osteoporosis are bone resorption inhibitors [[115], [116], [117]]. These drugs inhibit bone resorption

Bisphosphonates are inhibitors of bone resorption. They increase bone mineral density by altering osteoclast activation and function. Alendronate and